VIRTTU: Data Demonstrating That SEPREHVIR (Virttu Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.

GLASGOW, Scotland, Nov. 9, 2015 /PRNewswire/ -- VIRTTU Biologics, a clinical stage oncolytic immunotherapeutic company developing SEPREHVIR, a tumor-targeted herpes simplex vector, is pleased to announce the presentation of a poster by a key collaborator, Dr. Tim Cripe (Nationwide...